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OBJECTIVES We examined whether amlodipine, a calcium channel antagonist with potent antioxidant
activity, inhibits doxorubicin-induced apoptosis in cultured neonatal rat cardiac myocytes.
BACKGROUND Recent studies have shown that doxorubicin induces apoptosis as well as necrosis in myocytes
through generation of reactive oxygen species.
METHODS The effects of amlodipine and several other antioxidants on doxorubicin-induced oxidative
stress and mitochondria-mediated apoptosis were examined.
RESULTS Treatment of myocytes with doxorubicin (106 mol/l) for 14 h increased the number of cells
with elevated peroxides, as histochemically estimated by 2,7-dichlorofluorescin (DCF)
diacetate, and the percentage of apoptotic myocytes, as estimated by Hoechst 33258 nuclear
staining, compared with control myocytes (25.0  1.6% vs. 5.2  1.2%). Moreover,
doxorubicin-induced myocyte apoptosis was also confirmed by annexin V–fluorescein
isothiocyanate binding assay. Doxorubicin induced a reduction in myocyte adenosine
5-triphosphate content, a loss of mitochondrial membrane potential, cytochrome c release
from the mitochondria into the cytosol, and caspase-3 activation to 1.9-fold of control.
Amlodipine significantly attenuated increased DCF fluorescence, inhibited the mitochondria-
mediated apoptotic responses described earlier, and decreased apoptosis in the doxorubicin-
treated myocytes in a dose-dependent fashion. Amlodipine at 106 mol/l significantly
decreased apoptosis to 15.4 0.7%, and this antiapoptotic action was more effective than that
seen with other antioxidants, including probucol, ascorbic acid, and alpha-tocopherol. In
contrast, the calcium channel antagonist nifedipine (106 mol/l) did not inhibit apoptosis.
Catalase, glutathione, and N-acetylcysteine, but not mannitol or superoxide dismutase,
significantly decreased DCF fluorescence and attenuated myocyte apoptosis induced by
doxorubicin to 18.7  1.2%, 19.1  1.7%, and 18.7  0.6%, respectively.
CONCLUSIONS Amlodipine significantly inhibits doxorubicin-induced myocyte apoptosis by suppressing the
mitochondrial apoptotic pathway. This effect is attributed to the antioxidant properties of
amlodipine, affecting mainly hydrogen peroxide. (J Am Coll Cardiol 2003;41:870–8)
© 2003 by the American College of Cardiology Foundation
The anthracycline derivative doxorubicin is widely used to
treat various types of cancer; however, its clinical use is
limited by dose-dependent cardiotoxicity, leading to severe
congestive heart failure, often termed “doxorubicin cardio-
myopathy.” Several hypotheses have been proposed to
account for doxorubicin cardiotoxicity, including free radical
formation (1,2), impaired adrenergic regulation (3), release
of vasoactive amines (4), altered calcium handling (5),
mitochondrial impairment (6), suppression of muscle-
specific genes (7), and ceramide generation (8). The most
thoroughly investigated hypothesis for doxorubicin-induced
cardiotoxicity is based on the formation of reactive oxygen
species, such as superoxide and hydrogen peroxide, by
reactions catalyzed by the quinone moiety of doxorubicin
(6). Moreover, recent studies have demonstrated that, in
addition to necrosis, doxorubicin can induce myocyte apo-
ptosis through the Fas-mediated pathway (9), ceramide
generation (8), or reactive oxygen species (10,11). These
findings suggest that myocyte apoptosis contributes to the
development of myocardial loss and severe contractile dys-
function during the pathogenesis of doxorubicin cardiomy-
opathy.
Several antioxidants, including probucol (12) and dexra-
zoxane (13), have been suggested to prevent anthracycline-
induced cardiotoxicity. Antioxidant therapy may therefore
be useful in the management of doxorubicin cardiomyopa-
thy. To date, however, treatment with antioxidants has not
been shown to be clinically effective. Furthermore, the
molecular mechanisms by which doxorubicin-activated ox-
idative stress induces myocyte injury and antioxidants pre-
vent doxorubicin-induced myocyte death remain poorly
understood. As recent studies have demonstrated that reac-
tive oxygen species may also induce myocyte apoptosis
(14,15), we hypothesized that some antioxidants can effec-
tively inhibit doxorubicin-induced myocyte apoptosis by
scavenging reactive oxygen species.
Amlodipine is a newer member of the dihydropyridine
subclass of calcium channel antagonists. It has strong
membrane-lipid antioxidant activity that is entirely inde-
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pendent of calcium channel modulation. A lack of adverse
effects on morbidity and mortality in patients with severe
congestive heart failure (as demonstrated in the Prospective
Randomized Amlodipine Survival Evaluation [PRAISE]
trials) indicates that amlodipine has an unusual pharmaco-
logic profile, providing advantages over other calcium an-
tagonists (16). In pilot studies, we have confirmed that
amlodipine strongly inhibits doxorubicin-induced apoptosis
of cultured neonatal rat cardiac myocytes. In the present
study, we examined the mechanisms by which doxorubicin
induces and amlodipine inhibits myocyte apoptosis. We
have clearly demonstrated that amlodipine attenuates
doxorubicin-induced oxidative stress and significantly in-
hibits myocyte death by inhibiting the mitochondrial apo-
ptotic pathway.
METHODS
Culture of neonatal rat cardiac myocytes. Primary neo-
natal rat cardiac myocytes were prepared as described
previously, with some modifications (17,18). We routinely
obtained contractile, myocyte-enriched cultures with 95%
myocytes. Before the experiments, the cells were grown for
36 to 48 h in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 0.5% fetal bovine serum.
Experimental protocols. Cell cultures were washed twice
with phosphate-buffered saline (PBS), followed by a final
incubation in serum-deprived medium. During this final
incubation, cardiac myocytes were treated with one of the
following: 1) doxorubicin at 106 mol/l; 2) doxorubicin at
106 mol/l in the presence of amlodipine (109 to 105
mol/l); or 3) doxorubicin at 106 mol/l in the presence of
nifedipine (106 mol/l). To study the effects of several
antioxidants on doxorubicin-induced apoptosis, the myo-
cytes were treated with doxorubicin (106 mol/l) in the
presence of: 4) probucol (105 to 104 mol/l); 5) ascorbic
acid (5  105 mol/l); 6) alpha-tocopherol (104 mol/l);
7) catalase (4  104 U/l); 8) glutathione (15  103 mol/l);
9) N-acetylcysteine (NAC) (104 mol/l); 10) mannitol
(2  102 mol/l); or 11) superoxide dismutase (SOD)
(1.2  105 U/l). Unless otherwise indicated, treatment was
continued for 14 h, at which time we examined cell death
and apoptosis-associated signaling cascades by histochemi-
cal and biochemical methods. Control myocytes were incu-
bated in serum-deprived DMEM but were not treated with
any chemical.
Histochemical determination of cell viability and apo-
ptosis. The relative number of living and dead cells was
determined using a viability/cytotoxicity kit (Molecular
Probes, Eugene, Oregon) (19). Apoptotic cells were iden-
tified by the distinctive condensed or fragmented nuclear
structure in cells stained with 0.5 g/ml of Hoechst 33258
(Molecular Probes), as described previously (20). The cells
were photographed with the use of fluorescence microscopy.
An average of 800 to 1,000 nuclei from randomly selected
fields was analyzed for each experiment, and the number of
apoptotic cells was expressed as a percentage of the total
number of nuclei counted.
Apoptotic cells were also assessed using annexin V
labeling (21). The myocytes on coverslips were washed with
ice-cold PBS. Then, 100 l of diluted annexin V–fluores-
cein isothiocyanate (FITC) solution (Sigma, St. Louis,
Missouri) was added to the myocytes. The cells were then
incubated at room temperature, in the dark for 1 h on a
swirling base. The annexin V solution was removed and the
myocytes were washed once with PBS. Annexin V binding
was analyzed by fluorescent microscopy. For apoptosis
quantification by annexin V, the myocytes were scraped and
stained with annexin V–FITC, according to the manufac-
turer’s instructions. After 15-min incubation on ice, apo-
ptotic cells were measured by fluorescence-activated cell
sorter analysis (Becton Dickinson, San Jose, California).
Measurement of adenosine 5-triphosphate (ATP) content.
The ATP content of myocytes was measured after treat-
ment with doxorubicin in the presence or absence of either
amlodipine or nifedipine. Following lysis with perchloric
acid, cell supernatants were analyzed by high-performance
liquid chromatography, as described previously (22).
Myocyte oxidative stress. 2,7-Dichlorofluorescin di-
acetate (H2DCFDA) (Molecular Probes) was used to
evaluate oxidative stress induced by doxorubicin. Perox-
ides can be detected with the use of the nonfluorescent
dye H2DCFDA, which can freely permeate cells. Once
inside the cells, H2DCFDA is hydrolyzed to 2,7-
dichlorofluorescein (DCF) and entrapped intracellularly.
Then, DCF interacts with peroxides, which convert it to
fluorescent DCF, a compound readily detected by a fluo-
rescence microscope (23,24). Activation of DCF is relatively
specific for the detection of hydrogen peroxide and second-
ary and tertiary peroxides. One hour before doxorubicin
treatment, H2DCFDA was added to the cell cultures, and
fluorescence from DCF was detected with excitation at
488 nm. H2DCFDA was prepared in ethanol and diluted
with myocyte culture medium to a final concentration of
5 mmol/l.
Measurement of mitochondrial membrane potential.
After treatment of myocytes with doxorubicin (106 mol/l)
in the presence or absence of amlodipine (106 mol/l) in
Abbreviations and Acronyms
ATP  adenosine 5-triphosphate
Bax  Bcl-2–associated X protein
DCF  2,7-dichlorofluorescein
DMEM  Dulbecco’s modified Eagle’s medium
FITC  fluorescein isothiocyanate
H2DCFDA  2,7-dichlorofluorescin diacetate
JC-1  5,5,6,6-tetrachloro-1,1,3-
tetraethylbenzimidazolylcarbocyanine
iodide
MAPK  mitogen-activated protein kinase
NAC  N-acetylcysteine
PBS  phosphate-buffered saline
SOD  superoxide dismutase
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serum-deprived medium for 14 h, the myocytes on cover-
slips were incubated in PBS containing 105 mol/l of
5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolyl-
carbocyanine iodide (JC-1; Molecular Probes) at 37°C for
5 min. Fluorescence was viewed at 527 and 590 nm with
excitation at 480 nm.
Western blot analysis. Myocyte cell fractions were used
(25). For cytochrome c determination, mitochondrial and
cytosolic fractions were subjected to electrophoresis and
blotting, and the blots were reacted with anti-cytochrome c
monoclonal antibody (Pharmingen, San Jose, California),
followed by horseradish peroxidase–conjugated anti-mouse
immunoglobulin G (Amersham, Buckinghamshire, UK).
Laser scanning densitometry was used for semiquantitative
analysis of the data.
Caspase-3 activities. The activities of caspase-3 were de-
termined with a CPP32 assay kit (MBL, Nagoya, Japan) by
detection of chromophore p-nitroanilide after cleavage from
the labeled substrate Asp-Glu-Val-Asp (DEVD)-p-
nitroanilide, as described previously (26).
Statistical analysis. Data are expressed as the mean
value  SEM of at least from six samples derived from six
separate experiments. Differences were analyzed by one-way
analysis of variance combined with the Bonferroni test, and
p values of 0.05 were considered statistically significant.
RESULTS
Detection of doxorubicin-induced cell injury. The effects
of doxorubicin treatment on cell viability (necrosis) and
apoptosis are illustrated in Figure 1A. Under control con-
ditions, the fraction of viable cells (fluorescent green) was
consistently 95%. Treatment of myocytes with doxorubi-
cin at 106 mol/l for 14 h did not increase either the fraction
of nonviable cells (red fluorescent nuclei) or creatine kinase
activity in the medium (data not shown). In contrast,
doxorubicin significantly increased the frequency of apopto-
tic cells with typical fragmented nuclei and condensed
chromatin on histochemical nuclear staining with Hoechst
33258, as compared with control myocytes.
Time course of doxorubicin-induced myocyte apoptosis.
The number of apoptotic myocytes did not significantly
change up to 14 h under control conditions (5.2 1.2%). In
contrast, the percentage of apoptotic myocytes significantly
increased to 11.6  0.8%, 21.1  0.8%, and 25.0  1.6%
after doxorubicin treatment for 5, 10, and 14 h, respectively.
Figure 1. (A) Histochemical determination of cell viability and apoptotic myocytes. Cardiac myocytes were treated with serum-free DMEM alone (a and
e), 106 mol/l of doxorubicin (b and f), 106 mol/l of doxorubicin in the presence of 106 mol/l of amlodipine (c and g), or 106 mol/l of doxorubicin
in the presence of 106 mol/l of nifedipine (d and h) for 14 h. The cells were then labeled with calcein acetoxymethyl ester and ethidium homodimer-1
(a– d) or stained with Hoechst 33258 (e– h) and visualized by fluorescence microscopy, as described in the Methods section. Photomicrographs are
representative of at least three experiments for each experiment (acetoxymethyl ester and ethidium homodimer-1: magnification  200; Hoechst 33258:
magnification  400). (B) The effect of calcium channel antagonists on myocyte apoptosis. Myocytes were treated with 106 mol/l of doxorubicin in the
presence or absence of either amlodipine (109 to 105 mol/l) or nifedipine (106 mol/l) for 14 h. Fluorescent-stained nuclei of apoptotic myocytes were
analyzed morphologically and expressed as the percentage of total nuclei, as described in Methods. Control myocytes were incubated in serum-deprived
DMEM without any chemicals (n  6). *p  0.0001 vs. control. †p  0.0001 vs. doxorubicin.
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Doxorubicin at 106 mol/l thus significantly increased the
percentage of apoptotic myocytes, estimated by Hoechst
33258 staining, in a time-dependent fashion.
Effect of amlodipine on doxorubicin-induced apoptosis.
Amlodipine at 106 mol/l markedly decreased the number
of apoptotic myocytes with fragmented nuclei induced by
doxorubicin (Fig. 1A). Figure 1B shows the effect of either
amlodipine (109 to 105 mol/l) or nifedipine (106 mol/l)
on doxorubicin-induced myocyte apoptosis. Amlodipine in-
hibited myocyte apoptosis in a dose-dependent fashion, and
the percentage of myocytes showing doxorubicin-induced ap-
optosis was significantly inhibited to 16.4  1.2% and 15.4 
0.7% with 107 mol/l and 106 mol/l of amlodipine, respec-
tively, whereas amlodipine at 105 mol/l did not significantly
decrease apoptotic myocytes any further. In contrast, the
calcium channel antagonist nifedipine at 106 mol/l did not
inhibit doxorubicin-induced myocyte apoptosis.
To confirm the results from Hoechst 33258 staining, an
annexin V–FITC binding assay was performed. As shown
in Figure 2A, doxorubicin at 106 mol/l increased the
number of annexin V–FITC–positive cells. Amlodipine at
106 mol/l decreased the number of doxorubicin-induced
apoptotic myocytes stained with annexin V–FITC, whereas
nifedipine at 106 mol/l did not. When myocyte apoptosis
was quantified by flow cytometry (Fig. 2B and 2C), the
percentage of apoptotic myocytes significantly increased to
20.6  0.9% after 106 mol/l of doxorubicin treatment,
compared with control. Amlodipine at 106 mol/l signifi-
cantly inhibited the percentage of doxorubicin-induced
apoptosis to 12.5  0.6%. In contrast, nifedipine at
106 mol/l did not inhibit doxorubicin-induced myocyte
apoptosis.
Myocyte ATP content. The ATP content was 21.6 
2.9 nmol/mg protein under control conditions. Treatment
of myocytes with 106 mol/l of doxorubicin for 14 h
significantly decreased the ATP content to 65.1% of
control. Amlodipine (109 to 106 mol/l) inhibited
doxorubicin-induced ATP depletion in a dose-dependent
Figure 2. Detection of apoptosis by annexin V–FITC binding. Cardiac myocytes were treated with serum-free DMEM alone (a), 106 mol/l of doxorubicin
(b), 106 mol/l of doxorubicin in the presence of 106 mol/l of amlodipine (c), or 106 mol/l of nifedipine (d) for 14 h. (A) The cells were then stained
with annexin V–FITC and visualized by fluorescence microscopy, as described in the Methods section. Photomicrographs are representative of at least three
experiments for each experiment (magnification  400). (B and C) Quantification of apoptosis in myocytes was determined by flow cytometric analysis.
Cells were harvested, stained with annexin V–FITC, and analyzed as described in Methods. The percentage of apoptotic myocytes was determined by
calculating the ratio of annexin V–FITC binding cells (M1) to total cells (n  6). *p  0.001 vs. control. †p  0.001 vs. doxorubicin.
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fashion, and the ATP content was significantly increased by
co-treatment with 106 mol/l of amlodipine to 83.0% of
control. In contrast, nifedipine did not increase the ATP
content of doxorubicin-treated myocytes.
Effect of antioxidants on myocyte apoptosis. To compare
the antiapoptotic activity of amlodipine with that of other
antioxidants, the effect of probucol, ascorbic acid, or alpha-
tocopherol on doxorubicin-induced myocyte apoptosis was
examined, as shown in Figure 3A. There was no cardio-
protective effect after treatment with 5  105 mol/l of
ascorbic acid. Although 104 mol/l of probucol and 104
mol/l of alpha-tocopherol significantly attenuated apoptosis
to 21.2  1.0% and 20.1  1.2%, respectively, these
treatments were significantly less effective than 106 mol/l
of amlodipine.
Reactive oxygen species produced by doxorubicin. Figure
4 shows the effects of the antioxidants catalase, glutathione,
NAC, mannitol, and SOD on doxorubicin-induced apo-
ptosis. Treatment of myocytes with catalase, glutathione,
and NAC, but not mannitol and SOD, significantly de-
creased apoptosis induced by doxorubicin to 18.7  1.2%,
19.1  1.7%, and 18.7  0.6%, respectively.
Doxorubicin at 106 mol/l increased the number of cells
with elevated peroxides, as histochemically estimated by
H2DCFDA (Fig. 3B). Co-treatment with amlodipine at
106 mol/l, probucol at 104 mol/l, or alpha-tocopherol at
104 mol/l markedly inhibited the intensity of DCF fluo-
rescence. In contrast, neither nifedipine at 106 mol/l nor
ascorbic acid at 5  105 mol/l affected DCF fluorescence.
Mitochondrial membrane potential and cytochrome c
release. The fluorescent green JC-1 exists as a monomer at
low membrane potential. However, at higher potentials,
JC-1 forms fluorescent red “J-aggregates.” The emission of
this dye can therefore be used to monitor mitochondrial
membrane potential in apoptotic cardiac myocytes (27).
Under control conditions, the myocytes showed red-orange
mitochondrial staining, indicative of normal high mem-
brane potentials (Fig. 5A). In contrast, myocytes treated
with doxorubicin at 106 mol/l showed green fluorescence,
indicating a loss of mitochondrial membrane potential, and
Figure 3. (A) Effect of antioxidants on myocyte apoptosis. Myocytes were treated with 106 mol/l of doxorubicin in the presence or absence of either
amlodipine (106 mol/l), probucol (105 to 104 mol/l), ascorbic acid (5  105 mol/l), or alpha-tocopherol (104 mol/l) for 14 h. Fluorescent-stained
nuclei of apoptotic myocytes were analyzed morphologically and expressed as the percentage of total nuclei, as described in the Methods section. Control
myocytes were incubated in serum-deprived DMEM without any chemicals (n  6). p  0.0001 vs. control. †p  0.05 vs. doxorubicin. ‡p  0.0001 vs.
doxorubicin. (B) Histochemical characterization of oxidative stress. 2,7-Dichlorofluorescin diacetate (H2DCFDA) was added to the cultures 1 h before
the myocytes were treated with the chemicals listed subsequently for 14 h. Myocytes were examined as described in Methods. (a) Control cardiac myocytes;
(b) 106 mol/l of doxorubicin; (c) 106 mol/l of doxorubicin in the presence of 106 mol/l of amlodipine; (d) 106 mol/l of doxorubicin in the presence
of 106 mol/l of nifedipine; (e) 106 mol/l of doxorubicin in the presence of 104 mol/l of probucol; (f) 106 mol/l of doxorubicin in the presence of 5 
105 mol/l of ascorbic acid; (g) 106 mol/l of doxorubicin in the presence of 104 mol/l of alpha-tocopherol; and (h) 106 mol/l of amlodipine alone.
Photomicrographs are representative of at least three experiments for each experiment (magnification  200).
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co-treatment with amlodipine at 106 mol/l increased the
fluorescent red intensity. As shown in Figure 5B and C,
cytochrome c was detected only in the mitochondrial frac-
tion under control conditions. However, after treatment
with doxorubicin at 106 mol/l, immunoreactivity of cyto-
chrome c in the mitochondria significantly decreased to
27.0  1.0% and simultaneously increased to 368  21% of
control levels in the cytosolic fraction. Furthermore, this
doxorubicin-induced translocation of cytochrome c was
significantly inhibited by co-treatment with amlodipine at
106 mol/l.
Caspase-3 activation. Caspase-3 activity in doxorubicin-
treated myocytes significantly increased by 1.9-fold, as
compared with control myocytes. Amlodipine at
106 mol/l, probucol at 104 mol/l, and alpha-tocopherol at
104 mol/l significantly inhibited doxorubicin-induced
caspase-3 activation to 1.3-fold, 1.6-fold, and 1.5-fold of
control, respectively, whereas nifedipine at 106 mol/l and
ascorbic acid at 5  105 mol/l did not (Fig. 6).
DISCUSSION
To our knowledge, our study demonstrated for the first
time that doxorubicin significantly increased the number of
DCF fluorescent-positive cells and induced myocyte apo-
ptosis by activating mitochondria-mediated apoptotic cas-
cades. Amlodipine significantly attenuated DCF fluores-
cence, inhibited a mitochondrial apoptotic response, and
finally decreased apoptosis in doxorubicin-treated myocytes.
Other antioxidants, such as probucol and alpha-tocopherol,
similarly decreased doxorubicin-induced myocyte apoptosis.
In contrast, nifedipine did not inhibit apoptosis without
affecting DCF fluorescence. Therefore, our data suggest
that amlodipine inhibits apoptosis by suppressing oxidative
stress, thereby protecting mitochondria.
Doxorubicin and myocyte apoptosis. We treated myo-
cytes with 106 mol/l of doxorubicin, a concentration
considered pharmacologically relevant and clinically achiev-
able, for 14 h (28). This concentration of doxorubicin
optimally induced myocyte apoptosis with typical frag-
mented nuclei or condensed chromatin in a time-dependent
fashion, without necrosis. Doxorubicin neither increased
myocytes showing a loss of membrane integrity and uptake
of ethidium homodimer-1 nor induced creatine kinase
release into the medium. The present data therefore suggest
that morphologic and biochemical features of doxorubicin-
treated cells are closely associated with apoptosis, but not
with necrosis, under our experimental conditions.
Doxorubicin appears to stimulate a variety of intrinsic
cascades leading to apoptosis of myocytes. Indeed, recent
reports have indicated that activation of the mitogen-
activated protein kinase (MAPK) superfamily (29), induc-
tion of Bcl-2–associated X protein (Bax) and activation of
caspase-3 (30), ceramide generation (8), and the Fas/Fas
ligand system (9) are involved in doxorubicin-induced
apoptotic signals. Our study showed that 106 mol/l of
doxorubicin induces the loss of mitochondrial membrane
potential, translocation of cytochrome c from the mitochon-
dria into the cytosol, and concomitant activation of
caspase-3, significantly increasing apoptotic myocytes.
Therefore, our data essentially support and extend the
results of Kotamraju et al. (11). Since we have confirmed
that an inhibitor of mitochondrial permeability transition,
cyclosporine A at 3  107 mol/l, significantly inhibited
doxorubicin-induced apoptosis to 17.6  0.8% (p  0.001
vs. doxorubicin alone) (data not shown), our data strongly
suggest that doxorubicin can evoke mitochondrial perme-
ability transition, as well as activate the mitochondrial
apoptotic pathway in myocytes. Moreover, an inhibitor of
extracellularly responsive kinase, PD98059 at 5  105
mol/l, or an inhibitor of p38 MAPK, SB203580 at 105
mol/l, did not significantly decrease apoptosis induced by
doxorubicin (data not shown), suggesting that the MAPK
pathway does not play a principal role in apoptotic cascades
under our experimental conditions.
An important mechanism of doxorubicin cardiotoxicity
involves redox activation of doxorubicin to a semiquinone
intermediate, which generates superoxide radicals on one-
electron reduction of oxygen (31,32), as well as hydrogen
peroxide and hydroxyl radicals (33,34). The increased DCF
fluorescence in the doxorubicin-treated cells in our study is
consistent with this oxidative mechanism of doxorubicin
cardiotoxicity. Although the intracellular localization of
reactive oxygen species formed by doxorubicin is still under
investigation (1,35), recent studies suggest that mitochon-
dria in which doxorubicin accumulates over time are the
target organelle of doxorubicin-induced toxicity in myocytes
(36,37). Moreover, mitochondrial enzymes have been dem-
onstrated to activate doxorubicin to form semiquinone
Figure 4. Effect of catalase (CAT), glutathione (GSH), NAC, mannitol
(MAN), and SOD on myocyte apoptosis. Myocytes were treated with 106
mol/l of doxorubicin in the presence or absence of either catalase (4  104
U/l), GSH (15  103 mol/l), NAC (104 mol/l), MAN (2  102
mol/l), or SOD (1.2  105 U/l). Fluorescent-stained nuclei of apoptotic
myocytes were analyzed morphologically and expressed as the percentage of
total nuclei, as described in the Methods section. Control myocytes were
incubated in serum-deprived DMEM without any chemicals (n 6). *p
0.0001 vs. control. †p 0.01 vs. doxorubicin. ‡p 0.0001 vs. doxorubicin.
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radicals and superoxide anions in isolated cardiac prepara-
tions (2,31,38). Previous studies have also indicated that
isolated mitochondria from doxorubicin-treated hearts show
uncoupling of oxidative phosphorylation (39), in agreement
with our ATP and JC-1 staining data. The available
evidence thus suggests that doxorubicin accumulated in
mitochondria generates cytotoxic reactive oxygen species
that cause an irreversible loss of mitochondrial transmem-
brane potential and trigger the mitochondrial apoptotic
pathway.
Figure 5. Loss of mitochondrial transmembrane potential and release of cytochrome c. A, Myocytes were treated with 106 mol/l of doxorubicin in the
presence or absence of 106 mol/l of amlodipine for 14 h. The cells were then stained with JC-1, as described in the Methods section, and fluorescence
was monitored at 527 and 590 nm (magnification 400). Control myocytes were incubated in serum-deprived DMEM without any chemicals. (a) Control
cardiac myocytes; (b) myocytes exposed to 106 mol/l of doxorubicin for 14 h; (c) myocytes exposed to 106 mol/l of doxorubicin in the presence of 106
mol/l of amlodipine for 14 h. B, Myocytes treated with 106 mol/l of doxorubicin in the presence or absence of 106 mol/l of amlodipine were harvested
for detection of cytochrome c. Mitochondrial and cytosolic fractions were prepared, and aliquots containing 20 g protein were subjected to Western blot
analysis and probed with antibody for cytochrome c, as described in Methods. Photomicrographs are representative of at least three experiments for each
experiment. C, Densitometric analysis of cytochrome c release. Levels of cytochrome c are shown as the percent change in the average from three
independent experiments, as compared with control. *p  0.01 vs. control. †p  0.01 vs. doxorubicin.
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Amlodipine and antioxidant property. Amlodipine is re-
ported to have a very high affinity for lipid constituents of
cellular membranes (i.e., amlodipine has a charged amino-
terminal structure by which amlodipine can easily combine
with phospholipids in cellular membrane and stay in it for a
long time) (40,41). Moreover, amlodipine has two hydrogen
atoms within the dihydropyridine rings. The hydrogen
atoms are thought to play an important role in quenching
reactive oxygen species (42). Our study demonstrated that
amlodipine significantly attenuated the intensity of DCF
fluorescence, preserved ATP content, inhibited the mito-
chondrial apoptotic response, and finally decreased
doxorubicin-induced myocyte apoptosis. These findings
suggest that amlodipine decreased doxorubicin-induced ox-
idative stress and inhibited the mitochondrial death signal-
ing cascade. Other antioxidants such as probucol and
alpha-tocopherol, but not nifedipine, similarly inhibited
apoptosis and decreased DCF fluorescence. The antiapop-
totic action of amlodipine is therefore attributed to antiox-
idant activity, although we have no good explanation for the
reversal of this antiapoptotic effect at 105 mol/l. The
molecular mechanism by which amlodipine inhibits the
mitochondrial apoptotic cascade should be further examined
in the future; however, our data provide evidence that
amlodipine directly quenches reactive oxygen species and
preserves mitochondrial membrane potential.
Our data also show that catalase, glutathione, and NAC,
but not mannitol and SOD, significantly decreased
doxorubicin-induced myocyte apoptosis, which suggests
that hydrogen peroxide, but not superoxide nor hydroxyl
radicals, plays an important part in the induction of
doxorubicin-induced apoptosis. Therefore, our results agree
with those of Kotamraju et al. (11), but are inconsistent with
the findings of Sawyer et al. (10), as they showed that
hydrogen peroxide was not involved in doxorubicin-induced
apoptosis. We are unable to explain this apparent discrep-
ancy. Moreover, we found that amlodipine inhibited apo-
ptosis more effectively than did either probucol or alpha-
tocopherol, although these antioxidants similarly decreased
DCF fluorescence. We again have no plausible explanation
for these results. However, we are interested in the possi-
bility that amlodipine produces endogenous nitric oxide (43)
and exerts additive antiapoptotic activity, as recent studies
have demonstrated that endogenous nitric oxide can inhibit
apoptosis by direct suppression of caspase-3–like activity
(44) or inhibition of mitochondrial permeability transition
(45). Further studies are needed to confirm these specula-
tions.
The treatment of anthracycline-induced cardiotoxicity
has received considerable attention for more than two
decades. In the present study, we showed that amlodipine
had higher antiapoptotic action than other antioxidants,
such as probucol, ascorbic acid, and alpha-tocopherol.
Although future studies will be needed to examine whether
amlodipine exerts antiapoptotic action in vivo, our findings
strongly suggest that amlodipine can be useful in the
management of doxorubicin cardiomyopathy.
Conclusions. The present study shows that doxorubicin
generates hydrogen peroxide and induces myocyte apopto-
sis. Amlodipine significantly inhibits doxorubicin-induced
apoptosis by suppressing the mitochondrial apoptotic path-
way through its antioxidant properties. Our data suggest
that antioxidant therapy with amlodipine may clinically pro-
vide cardioprotection against doxorubicin cardiomyopathy.
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